BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Liu CJ, Huang WL, Chen PJ, Lai MY, Kao JH, Chen DS. End-of-treatment virologic response does not predict relapse after lamivudine treatment for chronic hepatitis B. World J Gastroenterol 2004; 10(24): 3574-3578 [PMID: 15534909 DOI: 10.3748/wjg.v10.i24.3574]
URL: https://www.wjgnet.com/1007-9327/full/v10/i24/3574.htm
Number Citing Articles
1
Zebao He, Jiefei Wang, Kezhou Liu, Haibin Huang, Yao Du, Zongmei Lin, Miaoguo Cai, Xinghua Feng. Randomized trial of lamivudine, adefovir, and the combination in HBeAg-positive chronic hepatitis BClinics and Research in Hepatology and Gastroenterology 2012; 36(6): 592 doi: 10.1016/j.clinre.2012.05.012
2
Guideline on prevention and treatment of chronic hepatitis B in China (2005)Chinese Medical Journal 2007; 120(24): 2159 doi: 10.1097/00029330-200712020-00002
3
Shao-Ming Chiu, Yuan-Hung Kuo, Jing-Houng Wang, Chao-Hung Hung, Tsung-Hui Hu, Sheng-Nan Lu, Chien-Hung Chen. Associations of HBV Genotype B vs C Infection With Relapse After Cessation of Entecavir or Tenofovir TherapyClinical Gastroenterology and Hepatology 2020; 18(13): 2989 doi: 10.1016/j.cgh.2020.04.048
4
Yajun Song, Erhei Dai, Jin Wang, Hengjun Liu, Junhui Zhai, Cuiying Chen, Zongmin Du, Zhaobiao Guo, Ruifu Yang. Genotyping of hepatitis B virus (HBV) by oligonucleotides microarrayMolecular and Cellular Probes 2006; 20(2): 121 doi: 10.1016/j.mcp.2005.11.004
5
Tai–Chung Tseng, Chun–Jen Liu, Hung–Chih Yang, Tung–Hung Su, Chia–Chi Wang, Chi–Ling Chen, Stephanie Fang–Tzu Kuo, Chen–Hua Liu, Pei–Jer Chen, Ding–Shinn Chen, Jia–Horng Kao. High Levels of Hepatitis B Surface Antigen Increase Risk of Hepatocellular Carcinoma in Patients With Low HBV LoadGastroenterology 2012; 142(5): 1140 doi: 10.1053/j.gastro.2012.02.007
6
Young-Joo Jin, Kang Mo Kim, Dong-jun Yoo, Ju Hyun Shim, Han Chu Lee, Young-Hwa Chung, Yung Sang Lee, Dong Jin Suh. Clinical course of chronic hepatitis B patients who were off-treated after lamivudine treatment: analysis of 138 consecutive patientsVirology Journal 2012; 9(1) doi: 10.1186/1743-422X-9-239
7
Chun-Jen Liu, Jia-Horng Kao, Ding-Shinn Chen. Therapeutic implications of hepatitis B virus genotypesLiver International 2005; 25(6): 1097 doi: 10.1111/j.1478-3231.2005.01177.x
8
James Fung, Ching-Lung Lai, Yasuhito Tanaka, Masashi Mizokami, John Yuen, Danny Ka-Ho Wong, Man-Fung Yuen. The Duration of Lamivudine Therapy for Chronic Hepatitis B: Cessation vs. Continuation of Treatment After HBeAg SeroconversionThe American Journal of Gastroenterology 2009; 104(8): 1940 doi: 10.1038/ajg.2009.200
9
Seong Hee Kang, Keunhee Kang, Yeon Jong Eun, Young Sun Lee, Tae Suk Kim, Yang Jae Yoo, Sang Jun Suh, Eileen L. Yoon, Young Kul Jung, Ji Hoon Kim, Yeon Seok Seo, Hyung Joon Yim, Kwan Soo Byun. Antiviral response is not sustained after cessation of lamivudine treatment in chronic hepatitis B patients: A 10-year follow-up studyJournal of Medical Virology 2017; 89(5): 849 doi: 10.1002/jmv.24715